Passa al contenuto
Merck

SML0937

Darunavir

≥98% (HPLC), HIV protease inhibitor, powder

Sinonimo/i:

TMC-114, UIC-94017, [(1R,5S,6R)-2,8-dioxabicyclo[3.3.0]oct-6-yl] N-[(2S,3R)-4- [(4-aminophenyl)sulfonyl- (2-methylpropyl)amino]-3-hydroxy-1-phenyl- butan-2-yl]

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

10 MG

124,00 €

50 MG

488,00 €

124,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine in blocco

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C27H37N3O7S
Numero CAS:
Peso molecolare:
547.66
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Nome del prodotto

Darunavir, ≥98% (HPLC)

SMILES string

[H][C@]1([C@@H](OC(N[C@@H](CC2=CC=CC=C2)[C@@H](CN(S(C3=CC=C(N)C=C3)(=O)=O)CC(C)C)O)=O)CO4)[C@]4([H])OCC1

InChI

1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1

InChI key

CJBJHOAVZSMMDJ-HEXNFIEUSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 20 mg/mL, clear

shipped in

wet ice

storage temp.

−20°C

Quality Level

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
SML0685SML1883SML2357
Darunavir ≥98% (HPLC)

Sigma-Aldrich

SML0937

Darunavir

Amprenavir ≥98% (HPLC)

Sigma-Aldrich

SML0685

Amprenavir

AR231453 ≥98% (HPLC)

Sigma-Aldrich

SML1883

AR231453

Isavuconazole ≥98% (HPLC)

Sigma-Aldrich

SML2357

Isavuconazole

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

-

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

-

Biochem/physiol Actions

Darunavir has been sanctioned by the food and drug administration (FDA) as the first treatment of drug-resistant human immunodeficiency virus (HIV).[1]
Darunavir is a HIV protease inhibitor; antiretroviral.
Darunavir is a second-generation antiviral HIV protease inhibitor with broad spectrum activity.

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Stein Schalkwijk et al.
Clinical pharmacokinetics, 57(6), 705-716 (2017-07-27)
Fetal antiretroviral exposure is usually derived from the cord-to-maternal concentration ratio. This static parameter does not provide information on the pharmacokinetics in utero, limiting the assessment of a fetal exposure-effect relationship. The aim of this study was to incorporate placental
Joseph J Eron et al.
AIDS (London, England), 32(11), 1431-1442 (2018-04-24)
To investigate efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg vs. darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate (TDF) (control) in antiretroviral-treatment-naive, HIV-1-infected adults. Phase-3, randomized, active-controlled, double-blind, international, multicenter, noninferiority study (NCT02431247). Seven hundred and twenty-five participants
Thomas N Kakuda et al.
Antiviral therapy, 19(6), 597-606 (2014-06-26)
Darunavir requires pharmacokinetic enhancement to increase its bioavailability. Cobicistat is potentially an alternative pharmacokinetic booster to ritonavir. Bioequivalence of a darunavir/cobicistat fixed-dose combination (FDC) versus darunavir and cobicistat co-administered as single agents and the effect of a high-fat meal on
David Wu et al.
Journal of clinical medicine, 9(6) (2020-06-21)
The current COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. The virus causes severe respiratory symptoms which manifest disproportionately in the elderly. Currently, there are over 6.5 million cases and 380,000 deaths reported. Given the current severity of the
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Ghosh A K, et al.
Bioorganic & Medicinal Chemistry, 15(24), 7576-7580 (2007)

Articoli

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Domande

Recensioni

Nessuna valutazione

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica